CClinicalTrials.gg
Status unknownNCT03838614Updated Feb 12, 2019

Gait and Muscle Power Training for Children With Developmental Coordination Disorder

An interventional study of Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT) and Rhythmical auditory stimulation gait training (RAS) in Developmental Coordination Disorder, sponsored by The University of Hong Kong. Status unknown at 1 site in Hong Kong. Open to participants aged 6 Years to 9 Years. Per ClinicalTrials.gov, last updated 2019-02-12.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
6 Years to 9 Years
Sex
All
01

Study summary

Objectives: To compare the effectiveness of RAS-MPT, RAS alone, MPT alone, and usual care (as a control) for improving the overall gait performance of and reducing falls in children with developmental coordination disorder (DCD) and to explore the relationship between gait performance and falls in this population.

Design: A randomized controlled trial. Sample: 76 children with DCD. Interventions: RAS-MPT, RAS alone, MPT alone, or usual care (12 weeks). Major outcomes: Outcomes will be evaluated at baseline, post-intervention, and a 6-month follow-up. Comprehensive gait analysis will produce spatiotemporal gait parameters (e.g., velocity and stride length), kinematic gait parameters (e.g., knee joint motions), and leg muscle EMG outcomes; an isokinetic test will quantify leg muscle strength and force production time; and fall histories will be obtained via interviews. Anticipated results and significance: The RAS-MPT group is predicted to display the best gait performance, which is associated with reduced fall incidents. This novel training regime can be readily adopted in school, clinical, or home settings to improve locomotor ability in children with DCD, an outcome with positive socioeconomic implications.

02

Conditions studied

  • Developmental Coordination Disorder

Browse trials for

03

In context

Motor Skills Disorders

94 studies on the registry are indexed under Motor Skills Disorders; 24 are open to participants now.

This study's planned enrollment of 76 is above the median of 40 across 67 interventional studies indexed under Motor Skills Disorders.

Browse Motor Skills Disorders studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,262 studies on the registry; 340 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 6 to 9 years old
  • classified as DCD according to the Diagnostic and Statistical Manual of Mental Disorders V
  • \< 5th percentile on the Movement Assessment Battery for Children-2 (MABC-2)
  • a total score of \< 46 (for children aged 6 to 7 years 11 months) or \< 55 (for children aged 8 to 9 years) on the DCD questionnaire 2007 (Chinese version)
  • attending a mainstream school (i.e., intelligence level within the normal range).

Exclusion criteria

Exclusion Criteria:

  • any congenital, cognitive, psychiatric (e.g., comorbid attention deficit hyperactivity disorder or autism spectrum disorder), neurological, sensory, hearing, visual, vestibular, musculoskeletal, or cardiopulmonary disorder that may affect test performance
  • obesity (body mass index [BMI] >95th percentile)
  • receiving active treatment such as physiotherapy
  • those unable to follow instructions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    RAS-MPT group

    Rhythmical auditory stimulation gait training and muscle power training group

    Behavioral: Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)

  • Experimental
    RAS group

    Rhythmical auditory stimulation gait training group

    Behavioral: Rhythmical auditory stimulation gait training (RAS)

  • Experimental
    MPT group

    Muscle power training group

    Behavioral: Muscle power training (MPT)

  • Other
    Control group

    Usual care group

    Other: Controls

Interventions

  • BehavioralRhythmical auditory stimulation gait training and muscle power training (RAS-MPT)

    The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.

  • BehavioralRhythmical auditory stimulation gait training (RAS)

    The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.

  • BehavioralMuscle power training (MPT)

    The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.

  • OtherControls

    Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.

06

What researchers measure

Primary outcomes

  1. Changes in spatiotemporal gait parameter - gait velocity (m/s)

    Time frame: 9 months

  2. Changes in spatiotemporal gait parameter - stride length (cm)

    Time frame: 9 months

  3. Changes in spatiotemporal gait parameter - cadence (steps/min)

    Time frame: 9 months

  4. Changes in spatiotemporal gait parameter - stance phase duration (% gait cycle)

    Time frame: 9 months

  5. Changes in spatiotemporal gait parameter - swing phase duration (% gait cycle)

    Time frame: 9 months

  6. Changes in spatiotemporal gait parameter - single-limb support durations (% gait cycle)

    Time frame: 9 months

  7. Changes in spatiotemporal gait parameter - double-limb support duration (% gait cycle)

    Time frame: 9 months

Secondary outcomes

  1. Changes in kinematic gait parameters

    Maximum knee and ankle angles during different gait phases

    Time frame: 9 months

  2. Changes in leg muscle peak electromyographic values

    Changes in leg muscle peak electromyographic values (in % of maximal voluntary isometric contraction) of rectus femoris, biceps femoris, tibialis anterior, and gastrocnemius medialis muscles

    Time frame: 9 months

  3. Changes in leg muscle maximum strength

    Changes in maximum muscle strength of knee extensors and flexors and ankle plantar flexors and dorsiflexors of the dominant leg as measured by dynamometry.

    Time frame: 9 months

  4. Changes in leg muscle force production time

    Changes in muscle force production time of knee extensors and flexors and ankle plantar flexors and dorsiflexors of the dominant leg as measured by dynamometry.

    Time frame: 9 months

  5. Changes in self-reported falls

    Children and parents will report the number of falls within the study period.

    Time frame: 9 months

07

Study locations

1 site
  • University of Hong Kong
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03838614
Lead sponsor
The University of Hong Kong
Responsible party
Shirley S.M. Fong (Principal Investigator, The University of Hong Kong) — Principal investigator
First posted
Feb 12, 2019
Start date
Jun 1, 2019 (estimated)
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Feb 12, 2019

Study contacts

Shirley Fong, PhD
Contact
smfong@hku.hk
28315260

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion